Abstract 4382
Background
Implementing screening programs for risk populations can reduce lung cancer mortality by detecting the disease at early stages, when surgical intervention or chemotherapy treatment can be conducted with best prognosis. Screening protocols based on Low-Dose CT presents a series of drawbacks and needs complementary methods for improving sensitivity and specificity in the screening procedure. Thermal Liquid Biopsy (TLB) is as a complementary technique that, combined with imaging techniques, may improve the efficacy of the screening method.
Methods
Blood samples from Healthy Controls (HC) and Lung Cancer Patients (LCP) were analyzed with a high sensitivity microcalorimeter VP-DSC (MicroCal – Malvern Panalytical). The data were processed in Origin 7.0 software. The plasma thermograms were analyzed through a multiparametric method developed by our research group. Statistical models allowed classifying the subjects according their serum thermograms.
Results
115 LCP subjects (average age 64.6±8.7, 83.0% men) with broad stage distribution (II: 5%, III: 26%; IV: 69%), smoking status (64% smoking, 7% non-smoking), histology distribution (37% adenocarcinoma, 29% squamous, 30% small cell) were compared to 119 HC subjects homogeneously distributed from a blood bank. TLB parameters obtained showed statistical differences between HC and LCP groups. Different statistical models were applied in order to establish the optimal TLB output, which is able to classify subjects according to their TLB thermogram: 92% success rate, 90% specificity, and 94% sensitivity (i.e., diagnostic odds ratio of 140).
Conclusions
High positive association between clinical groups and TLB multiparametric model offers advantages over current diagnosis techniques (LDCT imaging), providing a powerful diagnostic approach with a minimally-invasive, low-risk, low-cost clinical test for LCP. Future promising applications, such as screening programs, could be developed from TLB.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Instituto Carlos III (Spain).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3190 - GI101, a novel triple-targeting bispecific CD80-IgG4-IL2variant fusion protein, elicits synergistic anti-tumor effects in preclinical models
Presenter: Jae Chan Park
Session: Poster Display session 3
Resources:
Abstract
4062 - Phase 1b, open-label, dose-escalation study of M9241 (NHS-IL12) plus avelumab in patients (pts) with advanced solid tumors
Presenter: Julius Strauss
Session: Poster Display session 3
Resources:
Abstract
5777 - THOR-707, a novel not-alpha IL-2, promotes all key immune system anti-tumoral actions of IL-2 without eliciting vascular leak syndrome (VLS)
Presenter: Marcos Milla
Session: Poster Display session 3
Resources:
Abstract
5047 - A phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells
Presenter: Alessandra Curioni
Session: Poster Display session 3
Resources:
Abstract
1679 - HPV16 E6-specific TCR-T armored with checkpoint blockade in the treatment of cervical cancer
Presenter: Paul Bryson
Session: Poster Display session 3
Resources:
Abstract
1133 - the Mutant Neoantigen Specific T Cell Is a Personalized Immunotherapy in Refractory Solid Tumor
Presenter: Qi Song
Session: Poster Display session 3
Resources:
Abstract
3338 - NY-ESO-1 and LAGE1A –an emerging target for cell therapies in solid tumours
Presenter: Ioanna Eleftheriadou
Session: Poster Display session 3
Resources:
Abstract
3089 - Targeting myeloid-derived suppressor cells and T cells: combination treatment with MTL-CEBPA and PD-1 antibody in a mouse syngeneic CT26 model
Presenter: Mikael Sodergren
Session: Poster Display session 3
Resources:
Abstract
5991 - Master Checkpoint Cbl-b Inhibition: Anti-tumor Efficacy in a Murine Colorectal Cancer Model Following siRNA-based Cell Therapy
Presenter: Kathrin Thell
Session: Poster Display session 3
Resources:
Abstract
5007 - Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy
Presenter: Miren Zuazo
Session: Poster Display session 3
Resources:
Abstract